HB2164 • 2026

RELATING TO WORKERS' COMPENSATION.

Labor

Active

The official status still shows this bill as active or still awaiting another formal step.

Sponsor: SAYAMA, ILAGAN, KEOHOKAPU-LEE LOY, KUSCH, LEE, M., MARTEN, MATAYOSHI, OLDS, TAKAYAMA, WOODSON
Last action: 2026-03-17
Official status: Re-Referred to LBT/HHS, CPN/JDC.
Effective date: Not listed

Plain English Breakdown

The official source material does not provide specific details about federal standards or equivalent generic drug products, only defining compounded prescription drugs for workers' compensation purposes.

Workers' Compensation Law Changes

This bill updates Hawaii's workers' compensation laws to define 'compounded prescription drug'.

What This Bill Does

Defines 'compounded prescription drug' for the purposes of workers' compensation law.

Who It Names or Affects

Workers who receive workers' compensation benefits
Employers providing workers' compensation insurance
Pharmacists and physicians involved in compounding drugs for patients

Terms To Know

Compounded prescription drug: A medication made by a pharmacist or physician specifically for an individual patient based on a valid prescription order.

Limits and Unknowns

The bill does not affect rights and duties that matured before its effective date.
It is unclear how this change will impact existing workers' compensation claims involving compounded prescription drugs.

Amendments

These notes stay tied to the official amendment files and metadata from the legislature.

HD1

Hawaii published version HD1

Plain English: This amendment updates the definition of 'compounded prescription drug' in Hawaii's workers' compensation law to align with federal standards, ensuring patient safety and regulatory consistency.

Updates the definition of a 'compounded prescription drug' to match the federal standard under section 503A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353a).
Clarifies that compounded drugs must be made by a licensed pharmacist for an identified patient based on a valid prescription order.
Ensures that compounded drugs meet federal quality requirements.

The amendment specifies an effective date of July 1, 3000, which seems to be a placeholder or error and is not practical for implementation.

Bill History

2026-03-17 S
Re-Referred to LBT/HHS, CPN/JDC.
2026-03-12 S
Referred to LBT/HHS, JDC.
2026-03-12 S
Passed First Reading.
2026-03-12 S
Received from House (Hse. Com. No. 371).
2026-03-10 H
Passed Third Reading with none voting aye with reservations; Representative(s) Pierick voting no (1) and none excused (0). Transmitted to Senate.
2026-03-06 H
Reported from CPC (Stand. Com. Rep. No. 1052-26), recommending passage on Third Reading.
2026-03-04 H
The committee on CPC recommend that the measure be PASSED, UNAMENDED. The votes were as follows: 10 Ayes: Representative(s) Matayoshi, Grandinetti, Chun, Ilagan, Ichiyama, Iwamoto, Kong, Lowen, Marten, Tam; Ayes with reservations: none; Noes: none; and 1 Excused: Representative(s) Pierick.
2026-03-03 H
Bill scheduled for decision making on Wednesday, 03-04-26 2:00PM in conference room 329 VIA VIDEOCONFERENCE.
2026-03-03 H
The committee(s) on CPC recommend(s) that the measure be deferred until 03-04-26.
2026-02-27 H
Bill scheduled to be heard by CPC on Tuesday, 03-03-26 2:00PM in House conference room 329 VIA VIDEOCONFERENCE.
2026-02-20 H
Passed Second Reading as amended in HD 1 and referred to the committee(s) on CPC with none voting aye with reservations; none voting no (0) and Representative(s) Quinlan excused (1).
2026-02-20 H
Reported from LAB (Stand. Com. Rep. No. 634-26) as amended in HD 1, recommending passage on Second Reading and referral to CPC.
2026-02-17 H
The committee on LAB recommend that the measure be PASSED, WITH AMENDMENTS. The votes were as follows: 6 Ayes: Representative(s) Sayama, Lee, M., Garrett, Kapela, Kong, Reyes Oda; Ayes with reservations: none; Noes: none; and Excused: none.
2026-02-13 H
Bill scheduled to be heard by LAB on Tuesday, 02-17-26 9:00AM in House conference room 309 VIA VIDEOCONFERENCE.
2026-01-30 H
Referred to LAB, CPC, referral sheet 5
2026-01-28 H
Introduced and Pass First Reading.
2026-01-26 H
Pending introduction.

Official Summary Text

RELATING TO WORKERS' COMPENSATION.
Workers' Compensation; Benefits; Compounded Prescription Drugs
Defines compounded prescription drugs for the purposes of workers' compensation law. Effective 7/1/3000. (HD1)

Current Bill Text

Read the full stored bill text

HB2164

HOUSE OF REPRESENTATIVES

H.B. NO.

2164

THIRTY-THIRD LEGISLATURE, 2026

STATE OF HAWAII

A BILL FOR AN ACT

relating
to workers' compensation
.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

����
SECTION
1.
�
The legislature finds that workers'
compensation costs and transparency are critical to maintaining fair and
predictable benefits for injured workers while controlling employer expenses.
�
The legislature further finds that compounded
prescription drugs can provide essential therapeutic options for injured
workers when commercially available FDA approved medications are unsuitable due
to allergies, dosage requirements, or other clinical needs.
�
However, inconsistent definitions have led to
confusion.
�
Federal law under section
503A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353a) establishes
clear standards for pharmacy compounding, including patient specific
prescriptions, quality requirements for bulk substances, and exclusions for
simple reconstitution.
�
Aligning state
law with these standards will promote patient safety by ensuring compounded
drugs meet recognized quality benchmarks, enhance regulatory consistency
between state and federal oversight.

����
Accordingly,
the purpose of this Act is to align state law with federal standards for
pharmacy compounding by codifying the federal definition of a "compounded
drug", thereby promoting regulatory consistency, supporting patient
safety, and ensuring access to individualized medications when an FDA approved
drug is not medically appropriate for a particular patient.
�
This Act incorporates by reference section
503A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353a) and
clarifying federal guidance.

����
SECTION
2
.
�
Section 386-21.7, Hawaii Revised Statutes, is
amended by amending subsection (f) to read as follows:

����
"(f)
�
For purposes of this section[
,
"equivalent
]
:

����
"Compounded
prescription drug" means a drug product that is compounded by a licensed
pharmacist in a state licensed pharmacy, or a licensed physician, for an
identified individual patient based on the receipt of a valid prescription
order or a notation, approved by the prescribing practitioner, on the
prescription order that a compounded product is necessary for the identified
patient, and otherwise meets the requirements of
�
title 21 United States Code section 353.

����
"Equivalent

generic drug product" has the same meaning as provided in section 328-91."

����
SECTION 3.
�
This Act does not affect rights and duties
that matured, penalties that were incurred, and proceedings that were begun
before its effective date.

����
SECTION
4.
�
Statutory material to be repealed is
bracketed and stricken.
�
New statutory
material is underscored.

����
SECTION 5.
�
This Act shall take effect on July 1, 2026.

INTRODUCED BY:

_____________________________

Report Title:

Workers'
Compensation; Benefits; Compounded Prescription Drugs

Description:

Defines
compounded prescription drugs for the purposes of workers' compensation law.

The summary description
of legislation appearing on this page is for informational purposes only and is
not legislation or evidence of legislative intent.